University of California

The United States Government As Represented by the Department of Veterans Affairs

Victor Nizet

George Y Liu

Yongcheng Song

Eric Oldfield

Nina Van Sorge

Richard L Gallo

Ethan Bier

James Friend

Gopesh Tilvawala

Annabel Guichard

Mohamed Zaiou

Sean Collignon

William Connacher

Monika Kumaraswamy

Articles of manufacture, including an apparatus for acoustic wave based atomization, are provided. The apparatus may include a monocrystalline piezoelectric substrate. The monocrystalline piezoelectric substrate may include a surface patterned with at least one wetting region. The monocrystalline piezoelectric substrate may be configured to respond to an electric signal by at least generating acoustic waves including, for example, surface acoustic waves, Bluestein-Gulayev waves, Lamb waves, Love waves, flexural waves, thickness mode vibrations, mixed-mode waves, longitudinal waves, shear mode vibrations, and/or bulk wave vibrations. The acoustic waves may atomizing at least a portion of a material collected within the at least one wetting region to form a mist of the material. Methods for acoustic wave based atomization are also provided.

Acoustic wave atomizer

In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A(GAS), Group C(GCS), or Group A(GGS), infections, or other pathogenicinfections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A(GAS), Group C(GCS), or Group A(GGS), infections, or other pathogenicinfections.

Streptococcal GlcNAc-lacking glycopolypeptides, cell wall carbohydrates,vaccines, and methods for making and using them

Methods and pharmaceutical compositions for treating diseases characterized by compromised epithelial or endothelial barrier integrity are provided. The pharmaceutical compositions include an effective amount a Epac/Rap1 signaling inhibitor. The methods include administering to a patient suffering from a disease characterized by compromised epithelial or endothelial barrier integrity a therapeutically effective amount of a Epac/Rap1 signaling inhibitor, such as ESI-09, SecinH3, Slit, or AG1024.

Pharmacological restoration of epithelial or endothelial barrier integrity by agents blocking EPAC/RAP1 signaling

Streptococcal GlcNac-lacking gylcopolypeptides, cell wall carbohydrates,vaccines, and methods for making and using them

The disclosure provides compounds and methods to treat a microbial or a bacterial pathogenesis, and demonstrates that thepigment is a virulence factor and potential novel target for antimicrobial therapy.

Antimicrobial compositions for treating microbial infections

The disclosure provides a molecular genetic approach of targeted mutagenesis and heterologous expression, coupled with in vitro and in vivo models of bacterial pathogenesis, to demonstrate that thepigment is a virulence factor and potential novel target for antimicrobial therapy.

Antimicrobial therapy for bacterial infections

The disclosure provides compounds and methods to treat bacterial pathogenesis, and demonstrates that thepigment is a virulence factor and potential novel target for antimicrobial therapy.

The disclosure provides a novel class of cationic cathelin-like peptides and polypeptides that have antimicrobial activity. These peptides are useful for inhibiting microbial infection or growth.

Growing community of inventors

San Diego, CA, United States of America

Victor Nizet